At the Intersection of Science and Law
14 episodes - English - Latest episode: about 1 year ago -In DLA Piper’s At the Intersection of Science and Law podcast, members of the firm’s Life Sciences team explore the connection between science and the law in areas that include AI and drug discovery, mRNA technology, and the regulatory implications of new drugs and devices.
Homepage Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Episodes
Life sciences companies and the risks posed by the mifepristone litigation
May 19, 2023 15:54 - 33 minutes - 30.5 MBIn this episode, a cross-disciplinary team of FDA regulatory lawyers and life sciences litigators discuss the implications of the mifepristone litigation for life sciences companies as it pertains to citizen petitions, FDA approvals, and strategies manufacturers might consider going forward. See omnystudio.com/listener for privacy information.
Trade secrets protection in the life sciences sector
April 12, 2023 13:33 - 21 minutes - 19.6 MBDLA Piper’s Roberto Valenti and Ray Miller discuss trade secrets protection in the US and Europe and the peculiarities within the life sciences sector. Our speakers provide pragmatic approaches and suggestions on how to manage trade secrets for both pharmaceutical companies and medical device manufacturers. See omnystudio.com/listener for privacy information.
Cross-border considerations for privacy in clinical trials
February 06, 2023 16:11 - 18 minutes - 16.8 MBPublished in Chambers Expert Focus. With the recent publication of our Cross-border Guide to Clinical Trials and Privacy, James Clark, Paula Gonzalez de Castejón and David Kopans discuss ongoing and developing EU and US perspectives on privacy considerations with respect to cross-border clinical trials. See omnystudio.com/listener for privacy information.
Global Life Sciences Supply Chain Insights
November 03, 2022 17:22 - 27 minutes - 25.3 MBPublished in Chambers Expert Focus. Lauren Murdza and Richard Taylor share their insights on supply chain issues in the life sciences sector in the latest episode of At the Intersection of Science and Law. See omnystudio.com/listener for privacy information.
AI risk assessments: Future-proofing your innovation when rules can change mid-game
September 06, 2022 16:54 - 24 minutes - 22.7 MBPublished in Chambers Expert Focus. DLA Piper partner Danny Tobey is joined by Aviva Wein, Assistant General Counsel at Johnson & Johnson, to discuss how medical device and pharmaceutical companies are future-proofing their innovations in artificial intelligence as new regulations and risks arise. See omnystudio.com/listener for privacy information.
The rise of telehealth amid the COVID-19 pandemic
June 01, 2022 20:14 - 38 minutes - 35 MBKristi Kung is joined by Greg Bodulovic to discuss digital health and its rise during the COVID-19 pandemic as well as advancements in technology that address healthcare access. See omnystudio.com/listener for privacy information.
The rise of global telehealth
June 01, 2022 20:14 - 25 minutes - 23.5 MBDLA Piper partners Kristi Kung and Greg Bodulovic discuss the rise of telehealth amid the COVID-19 pandemic, as well as advancements in technology aiming to address disparate access to healthcare globally. See omnystudio.com/listener for privacy information.
Advising the advisor: Tips for navigating the life sciences and regulatory environment
April 18, 2022 17:30 - 31 minutes - 28.4 MBDLA Piper managing partner Emilio Ragosa is joined by Kevin Sheridan, Joint Global Head of Healthcare Investment Banking at Jefferies LLC, to discuss the importance of advisors having an understanding of the life sciences industry in order to provide value-added advice on transactions, including public offerings and M&A. See omnystudio.com/listener for privacy information.
The moral imperative: Balancing innovation, regulation and prescription drug availability
March 21, 2022 17:34 - 30 minutes - 28 MBDLA Piper's Jim Greenwood and Geoff Levitt are joined by Peter Kolchinsky, founding Partner and Portfolio Manager at RA Capital, to discuss the importance of – and complications in – balancing biopharmaceutical innovation, industry regulations and prescription drug availability. See omnystudio.com/listener for privacy information.
Incentivizing diverse representation in clinical trials
March 02, 2022 18:42 - 22 minutes - 20.8 MBDiverse representation in clinical trials is critical in achieving greater equity and better healthcare outcomes. DLA Piper's Kirsten Axelsen and Sarah Schick are joined by Shazia Ahmad, Senior Director and Head of Patient and Physician Services at UBC, to discuss the importance of regulatory incentives to drive racial and ethnic diversity in clinical trials. See omnystudio.com/listener for privacy information.
The crossroad of science and law
December 16, 2021 19:15 - 26 minutes - 24.1 MBDLA Piper’s Lucas Przymusinski and Raymond Williams are joined by Michael King, Vice President and Associate General Counsel at Jazz Pharmaceuticals, to discuss the benefits of medical and science backgrounds when litigating matters for pharmaceutical and medical device companies. See omnystudio.com/listener for privacy information.
Social media’s impact on the life sciences industry
November 08, 2021 19:47 - 34 minutes - 32 MBDLA Piper’s Chris Campbell and Jody Rhodes are joined by Sarah Heineman, Senior Assistant General Counsel at Bayer, to discuss how social media affects the public's view of medicine and science and how that in turn impacts the life sciences industry, including litigation. See omnystudio.com/listener for privacy information.
Understanding AI and its use in drug discovery
October 05, 2021 21:08 - 31 minutes - 29.2 MBDLA Piper partners Ellen Scordino and Susan Krumplitsch are joined by Duane Valz, General Counsel of Insitro, to discuss how machine learning is being used to generate and leverage data for the development of better medicines. See omnystudio.com/listener for privacy information.
mRNA technology and the COVID-19 vaccine: A conversation with Pfizer’s Kathy Fernando
September 03, 2021 16:45 - 26 minutes - 24.2 MBFor decades, scientists have studied the seemingly endless possibilities of custom-made messenger RNA, or mRNA. Kathy Fernando, Head Vice President, Worldwide of Clinical Operations at Pfizer, spent her early bench science career working with mRNA technology and had a front row seat to the creation of the COVID-19 vaccine. DLA Piper’s Dr. Lisa Haile talks with Dr. Fernando about the study of mRNA and how COVID-19 catalyzed its advancement. See omnystudio.com/listener for privacy information.